Fig 1: Increased expression of EMT-related proteins in pancreatic TSs under 3D co-culture conditions with stromal cells. (A) Expression level of vimentin, TGF-β1, and CTGF in PANC-1 TSs with or without aPSCs, M2 THP-1 cells, or both. (B,C) Expression level of vimentin and E-cadherin, which are representative EMT markers, in BxPC-3 and Capan-1 TSs with or without aPSCs, M2 THP-1 cells, or both. Cells were counterstained with DAPI. aPSCs and M2 THP-1 cells were pre-conditioned before loading into the microfluidic channels. Data represent the mean ± SD of three independent experiments. Scale bar: 50 µm, * p < 0.05 compared to TSs cultured alone. # p < 0.05 compared to TSs co-cultured with either aPSCs or M2 THP-1 cells. Cells were grown for 5 days before analysis.
Fig 2: Kaplan-Meier survival analysis of 71 colorectal cancer patients from the time of diagnosis of the disease with connective tissue growth factor protein expression. A: Overall survival (OS) with connective tissue growth factor (CTGF) High and low expression; B: Disease-free survival (DFS) with CTGF High and Low expression; C and D: Depict OS and DFS of colorectal cancer patients respectively stratified as Stage I + II and III + IV.
Fig 3: PEDF overexpression downregulates the activity of VEGF- regulated factors.(A) Decreased MMP2 and 9 activity in aqueous humour from TgIGF-I mice after AAV2-hPEDF treatment. (B) Transgenic mice showed increased CTGF accumulation in comparison with WT. CTGF levels were reduced after 6 months of AAV2-hPEDF treatment, but not after AAV2-null injection. N.I., non-injected. Values are expressed as the mean ±SEM of 4–10 animals/group. *P<0.05.
Fig 4: Regulation of the PI3K/AKT pathway in ARPE19 cells by CTGF. (A) Representative western blot analysis of p-PI3K/PI3K and p-Akt/Akt in ARPE19 cells treated with CTGF (15, 30 and 60 ng/ml). (B) Quantification of p-PI3K/PI3K levels; n=3. *P<0.05, ***P<0.001 vs. control group. CTGF, connective tissue growth factor; p-, phosphorylated.
Fig 5: Mediation of TGF-β1-stimulated collagen synthesis by CTGF. (A) Incorporation of [3H]proline by ARPE19 cells treated with CTGF (5, 15, 30 and 60 ng/ml). (B) Incorporation of [3H]proline by untreated ARPE19 cells and cells treated with 8-Br-cAMP (0.1 mM), CTGF (60 ng/ml) and CTGF (60 ng/ml) + 8-Br-cAMP (0.1 mM). *P<0.05, **P<0.01 vs. control; #P<0.05 vs. the CTGF group. (C) Incorporation of [3H]proline by CTGF-ODN-transfected ARPE19 cells treated with 15 ng/ml TGF-β1. The results are expressed as cpm/103 cells ± standard error of the mean; n=3. *P<0.05, **P<0.01 vs. control; #P<0.05 vs. the TGF-β1 group. CTGF, connective tissue growth factor; 8-Br, 8-Bromoadenosine; ODN, oligonucleotide; S, sense; A, antisense; cpm, counts per min.
Supplier Page from Abcam for Anti-CTGF antibody